Ann Hynes
Stock Analyst at Mizuho
(4.41)
# 340
Out of 5,042 analysts
268
Total ratings
64.5%
Success rate
12.89%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCA HCA Healthcare | Maintains: Outperform | $475 → $505 | $459.68 | +9.86% | 22 | Oct 27, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $575 → $655 | $584.91 | +11.98% | 5 | Oct 24, 2025 | |
| THC Tenet Healthcare | Maintains: Outperform | $194 → $225 | $206.49 | +8.96% | 16 | Oct 17, 2025 | |
| DGX Quest Diagnostics | Maintains: Outperform | $190 → $210 | $175.95 | +19.35% | 16 | Oct 17, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $285 → $320 | $253.96 | +26.00% | 16 | Oct 17, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $9 | $10.46 | -13.96% | 5 | Oct 17, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $155 → $174 | $180.07 | -3.37% | 3 | Oct 17, 2025 | |
| BTSG BrightSpring Health Services | Maintains: Outperform | $26 → $32 | $33.05 | -3.18% | 2 | Oct 17, 2025 | |
| UNH UnitedHealth Group | Maintains: Outperform | $300 → $430 | $341.56 | +25.89% | 21 | Oct 9, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $345 | $278.19 | +24.02% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $342 → $420 | $317.20 | +32.41% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $40 | $35.37 | +13.09% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $88 | $78.15 | +12.60% | 11 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $22 | $21.50 | +2.33% | 12 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $225 | $216.46 | +3.95% | 13 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $173 → $225 | $171.82 | +30.95% | 16 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $330 | $153.06 | +115.60% | 9 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $14.56 | +23.63% | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $16.97 | -11.61% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $190.77 | -37.10% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $19.92 | +40.56% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $113.85 | -16.56% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $244.41 | +57.52% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $217.01 | -7.84% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $2.31 | +11,501.73% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $811.34 | -37.76% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $21.93 | +128.00% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.40 | +3,971.43% | 1 | Sep 21, 2017 |
HCA Healthcare
Oct 27, 2025
Maintains: Outperform
Price Target: $475 → $505
Current: $459.68
Upside: +9.86%
Medpace Holdings
Oct 24, 2025
Maintains: Outperform
Price Target: $575 → $655
Current: $584.91
Upside: +11.98%
Tenet Healthcare
Oct 17, 2025
Maintains: Outperform
Price Target: $194 → $225
Current: $206.49
Upside: +8.96%
Quest Diagnostics
Oct 17, 2025
Maintains: Outperform
Price Target: $190 → $210
Current: $175.95
Upside: +19.35%
Labcorp Holdings
Oct 17, 2025
Maintains: Outperform
Price Target: $285 → $320
Current: $253.96
Upside: +26.00%
Fortrea Holdings
Oct 17, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $10.46
Upside: -13.96%
Charles River Laboratories International
Oct 17, 2025
Maintains: Neutral
Price Target: $155 → $174
Current: $180.07
Upside: -3.37%
BrightSpring Health Services
Oct 17, 2025
Maintains: Outperform
Price Target: $26 → $32
Current: $33.05
Upside: -3.18%
UnitedHealth Group
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $430
Current: $341.56
Upside: +25.89%
Humana
Oct 9, 2025
Maintains: Outperform
Price Target: $300 → $345
Current: $278.19
Upside: +24.02%
Oct 9, 2025
Maintains: Outperform
Price Target: $342 → $420
Current: $317.20
Upside: +32.41%
Oct 9, 2025
Maintains: Neutral
Price Target: $28 → $40
Current: $35.37
Upside: +13.09%
Oct 9, 2025
Maintains: Outperform
Price Target: $76 → $88
Current: $78.15
Upside: +12.60%
Aug 14, 2025
Maintains: Neutral
Price Target: $32 → $22
Current: $21.50
Upside: +2.33%
Jul 25, 2025
Maintains: Outperform
Price Target: $190 → $225
Current: $216.46
Upside: +3.95%
Jul 25, 2025
Maintains: Outperform
Price Target: $173 → $225
Current: $171.82
Upside: +30.95%
Jul 11, 2025
Maintains: Outperform
Price Target: $400 → $330
Current: $153.06
Upside: +115.60%
Apr 9, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $14.56
Upside: +23.63%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $16.97
Upside: -11.61%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $190.77
Upside: -37.10%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $19.92
Upside: +40.56%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $113.85
Upside: -16.56%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $244.41
Upside: +57.52%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $217.01
Upside: -7.84%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $2.31
Upside: +11,501.73%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $811.34
Upside: -37.76%
Jul 11, 2023
Maintains: Buy
Price Target: $48 → $50
Current: $21.93
Upside: +128.00%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.40
Upside: +3,971.43%